Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Reliable, Rapid, and Robust Speciation of Arsenic in Urine by IC-ICP-MS
Wegwerth, Peter J, Erdahl, Sarah A , Wermers, Michelle, Hanley, Matthew M., Eckdahl, Steve, Jannetto, Paul J. , Wermers, Michelle L, Eckdahl, Steve J

Mayo Clinic

The Journal of Applied Laboratory Medicine | November 29, 2020 | Volume: 6 | Issue: 4 | Pages: 846-857

10.1093/jalm/jfaa226 | PMID 33486508 Get It

Abstract Background Arsenic is a naturally occurring element with varying species and levels of toxicity. Inorganic arsenic (e.g., arsenite (AsIII) and arsenate (AsV)) are toxic, while its metabolites (e.g., monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)) are less toxic). Symptoms of exposure can include headaches, confusion, diarrhea, and drowsiness. As these symptoms overlap with many other conditions, arsenic exposure can often be overlooked as a cause. Arsenic toxicity may be treated with chelation and/or electrolyte replacement therapy. However, treatment is not without risks and is unnecessary for exposure to organic (nontoxic) forms of arsenic. This makes screening and differentiation of arsenic important for clinical testing. Method An IC-ICP-MS method was developed using a Dionex 5000 with ion exchange chromatography for separation and iCAP Q for detection. Nontoxic species are arsenobetaine and arsenocholine, and toxic species are AsIII, DMA, MMA, and AsV. Results Precision, linearity, and specificity studies produced acceptable results. For accuracy, proficiency testing and method comparison samples were analyzed and produced acceptable results. Carryover studies demonstrated single species carryover from the diluter at levels of 500 µg/L, which can be avoided by analysis rules in the standard operating procedure. Limit of detection studies yielded a lower limit of quantitation of 1 µg/L per species. Conclusions Here, we present a rapid and reliable method for quantifying and differentiating toxic and nontoxic forms of arsenic to allow for swift and appropriate management of patients with exposure.
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, Richard R. , Kingdom, Todd T. , Smith, Timothy L. , Bleier, Benjamin S. , DeConde, Adam S., Luong, Amber , Poetker, David M., Welch, Kevin C. , Wise, Sarah K. , Adappa, Nithin D. , Anselmo‐Lima, Wilma Terezinha , Bachert, Claus , Baroody, Fuad M. , Batra, Pete S., Bernal‐Sprekelsen, Manuel , Bhattacharyya, Neil , Chang, Eugene H., Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Noah , Conley, David B. , DelGaudio, John M. , Desrosiers, Martin , Douglas, Richard , Eloy, Jean Anderson , Gray, Stacey T. , Gudis, David A. , Hamilos, Daniel L. , Han, Joseph K., Harvey, Richard J. , Hellings, Peter W. , Hopkins, Claire , Hwang, Peter H. , Javer, Amin R. , Kennedy, David W. , Kern, Robert C. , Lee, Heung‐Man , Lee, Jivianne T. , Levy, Joshua M. , Lin, Sandra Y. , Lund, Valerie, McMains, Kevin C. , Metson, Ralph, Naclerio, Robert M. , Oakley, Gretchen M. , Otori, Nobuyoshi , Parikh, Sanjay R., Patel, Zara M. , Peters, Anju T. , Philpott, Carl , Roh, Hwan‐Jung , Rudmik, Luke , Sacks, Raymond , Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Sindwani, Raj , Smith, Kristine A. , Stewart, Michael G. , Suh, Jeffrey D. , Tan, Bruce K. , Drunen, Cornelis M. van , Woodworth, Bradford A. , Wormald, Peter‐John , Wright, Erin D. , Yan, Carol H. , Zhang, Luo , Zhou, Bing , Chang, Michael T. , Bleier, Benjamin , Alt, Jeremiah A , Beswick, Daniel , Eloy, Jean Anderson , Gudis, David A , Holbrook, Eric H , Hopkins, Claire , Javer, Amin R , Jiang, Rong-San , Lal, Devyani , Lee, Heung-Man , Levy, Joshua M , Patel, Zara , Philpott, Carl , Ramakrishnan, Vijay R , Smith, Kristine , Yan, Carol , Zhang, Luo , Schlosser, Rodney J , Harvey, Richard J , Hwang, Peter H , Chang, Michael T , Soler, Zachary M. , Adappa, Nithin D. , Alt, Jeremiah A. , Beswick, Daniel M. , Chandra, Rakesh Kumar , Chang, Eugene H., Chiu, Alexander G. , Cohen, Noam A., Fokkens, Wytske Johanna , Holbrook, Eric H. , Laidlaw, Tanya M. , Lal, Devyani , Lane, Andrew P , Mullol, Joaquim , Passàli, Desiderio , Psaltis, Alkis J. , Ramanathan, Murugappan , Snidvongs, Kornkiat , Turner, Justin H. , Voegels, Richard Louis , Wang, De Yun

Mayo Clinic

International Forum of Allergy & Rhinology | November 25, 2020 | Volume: 11 | Issue: 3 | Pages: 213-739

10.1002/alr.22741 | PMID 33236525 Get It

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
Use of telemedicine for ichthyosis: Patient advocacy group as conduit to expert physician advice
Asch, Sarah , Swink, Shane M. , Vivar, Karina L. , Pickford, Jean, Breuning, Lisa, Wassel, Christine, Hand, Jennifer L. , Milstone, Leonard M. , Castelo‐Soccio, Leslie , Milstone, Leonard , Castelo-Soccio, Leslie

Mayo Clinic

Pediatric Dermatology | November 24, 2020 | Volume: 38 | Issue: 1 | Pages: 137-142

10.1111/pde.14460 | PMID 33230835 Get It

AbstractBackground/ObjectivesPatients with rare diseases are challenged when it comes to finding physicians with expertise in their condition. The Foundation for Ichthyosis and Related Skin Types (FIRST) Tele‐Ichthyosis program has provided telemedicine for patients and their families with keratinizing disorders since 2009. This study aims to characterize a decade of experience with the program.MethodsThis retrospective cohort study analyzed cases for demographics of patients and the clinicians who submitted their cases, nature of questions asked, number of expert responses, and characteristics of responses. Surveys were sent electronically to all users of the FIRST Tele‐Ichthyosis service to assess experiences with the service and solicit constructive recommendations. Descriptive statistics were performed on the case review and responder surveys.ResultsEighty‐eight geographically diverse cases were reviewed showing increased use over time by various specialists for patients of all ages. Sixty‐six percent of cases were definitively ichthyosis, and most submitters queried on diagnosis (47%) or treatment (72%). Most submitters described the service as easy to use (66.6%) and advice as timely (61.1%), clear (66.6%), and beneficial (61.1%). All submitters made suggestions for improvement (100%). Experts predominately worked with pediatric populations (70%) and reported self‐motivation to volunteer and improve patients’ lives (100%). Experts found technological barriers minor and provided feedback to enhance the service.ConclusionsThis report highlights how a rare‐disease patient advocacy group successfully supports physician collaboration and patient outcomes through secure and efficient telemedicine. Lessons learned are highly relevant in the current healthcare environment.
Changing Medical Education When Change Is Hard: Implementing an Interdepartmental Entrustable Professional Activity
Collins, Eric , Schnapp, Benjamin , Westergaard, Mary , Greenberg, Jacob A. , Jung, Sarah , Rosser, Alexandra A., Minter, Rebecca M., Hamedani, Azita G., Kraut, Aaron , Kraut, Aaron , Stahl, Christopher C.

Mayo Clinic

AEM Education and Training | November 24, 2020 | Volume: 5 | Issue: 3 | Pages: No page available

10.1002/aet2.10561 | PMID 34124509 Get It

AbstractBackgroundEntrustable professional activities (EPAs) are a new tool for assessing learners that represents a significant movement in graduate medical education (GME) toward competency‐based assessment and serves as a bridge between milestones and clinical practice. Whenever a major change is implemented to any system, resistance to change is expected. Many change management models have been proposed to overcome this resistance; a newer model is outlined in the book Switch. The objective was to describe the change management principles used to institute an EPA.MethodsThe model introduced in Switch was used as a framework for implementing a trauma resuscitation EPA in a joint effort between the departments of surgery and emergency medicine (EM) at the University of Wisconsin Hospitals and Clinics. The Department of Emergency Medicine used the principles of change management, completing 295 faculty evaluations of trauma resuscitations compared to the Department of Surgery, whose faculty completed 50 evaluations between the study period of July 2018 through October 2019. A survey completed winter 2019 of EM faculty was used to determine the most important principles toward successful implementation.ResultsTwenty‐seven of 35 (78% response rate) of EM faculty identified key concepts from Switch as being instrumental in the successful implementation. Internal discussion of the implementation approach used by the Department of Surgery identified several limitations that would have been overcome by using these same change management principles.ConclusionWe conclude that the principles of change management provide a useful framework for successfully implementing EPAs into GME.
Racial differences in the association of accelerated aging with future cardiovascular events and all-cause mortality: the coronary artery risk development in young adults study, 2007–2018
Forrester, Sarah , Zmora, Rachel , Schreiner, Pamela J. , Jacobs, David R. , Roger, Véronique L. , Thorpe, Roland J. , Kiefe, Catarina I. , Forrester, Sarah N , Jacobs, David R

Mayo Clinic

Ethnicity & Health | November 21, 2020 | Volume: 27 | Issue: 5 | Pages: 997-1009

10.1080/13557858.2020.1839021 | PMID 33222499 Get It

Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Isganaitis, Elvira , Raghinaru, Dan, Ambler-Osborn, Louise, Pinsker, Jordan E. , Buckingham, Bruce A. , Ekhlaspour, Laya , Kudva, Yogish C., Forlenza, Gregory P. , Beck, Roy W., Kollman, Craig, Lum, John W. , Brown, Sue A. , Laffel, Lori M. , Kovatchev, Boris, Anderson, Stacey, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Laffel, Lori, Pinsker, Jordan, Doyle, Francis, Renard, Eric, Reznik, Yves , Lum, John, Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Green, Jennifer , Legault, Laurent , Wysham, Carol , Eggerman, Thomas, Forlenza, Gregory P , Buckingham, Bruce , Wadwa, R Paul , Kudva, Yogish C. , Levy, Carol J. , Kollman, Craig , Kovatchev, Boris , Anderson, Stacey M. , Oliveri, Mary Clancy , Kumari, Kanchan , Messer, Laurel H , Jacobson, Tali, Doyle, Francis J. , Patibandla, Nandan, Laffel, Lori M. , Cobelli, Claudio , Beck, Roy W. , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | November 20, 2020 | Volume: 23 | Issue: 5 | Pages: 342-349

10.1089/dia.2020.0572 | PMID 33216667 Get It

Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents and young adults with type 1 diabetes. Research Design and Methods: Prespecified subanalysis of outcomes in adolescents and young adults aged 14–24 years old with type 1 diabetes in a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) and followed for 6 months. Results: Mean age of the 63 participants was 17 years, median type 1 diabetes duration was 7 years, and mean baseline HbA1c was 8.1%. All 63 completed the trial. Time in range (TIR) increased by 13% with CLC versus decreasing by 1% with SAP (adjusted treatment group difference = +13% [+3.1 h/day]; 95% confidence interval [CI] 9–16, P < 0.001), which largely reflected a reduction in time >180 mg/dL (adjusted difference −12% [−2.9 h/day], P < 0.001). Time <70 mg/dL decreased by 1.6% with CLC versus 0.3% with SAP (adjusted difference −0.7% [−10 min/day], 95% CI −1.0% to −0.2%, P = 0.002). CLC use averaged 89% of the time for 6 months. The mean adjusted difference in HbA1c after 6 months was 0.30% in CLC versus SAP (95% CI −0.67 to +0.08, P = 0.13). There was one diabetic ketoacidosis episode in the CLC group. Conclusions: CLC use for 6 months was substantial and associated with improved TIR and reduced hypoglycemia in adolescents and young adults with type 1 diabetes. Thus, CLC has the potential to improve glycemic outcomes in this challenging age group. The clinical trial was registered with ClinicalTrials.gov (NCT03563313).
Development and Verification of a Digital Twin Patient Model to Predict Specific Treatment Response During the First 24 Hours of Sepsis
Lal, Amos , Cubro, Edin, Chalmers, Sarah , Li, Heyi , Pickering, Brian W. , Kılıçkaya, Oğuz , Li, Guangxi , Lal, Amos , Herasevich, Vitaly , Dong, Yue , Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | November 17, 2020 | Volume: 2 | Issue: 11 | Pages: e0249

10.1097/cce.0000000000000249 | PMID 33225302 Get It

Objectives: To develop and verify a digital twin model of critically ill patient using the causal artificial intelligence approach to predict the response to specific treatment during the first 24 hours of sepsis. Design: Directed acyclic graphs were used to define explicitly the causal relationship among organ systems and specific treatments used. A hybrid approach of agent-based modeling, discrete-event simulation, and Bayesian network was used to simulate treatment effect across multiple stages and interactions of major organ systems (cardiovascular, neurologic, renal, respiratory, gastrointestinal, inflammatory, and hematology). Organ systems were visualized using relevant clinical markers. The application was iteratively revised and debugged by clinical experts and engineers. Agreement statistics was used to test the performance of the model by comparing the observed patient response versus the expected response (primary and secondary) predicted by digital twin. Setting: Medical ICU of a large quaternary- care academic medical center in the United States. Patients or Subjects: Adult (> 18 year yr old), medical ICU patients were included in the study. Interventions: No additional interventions were made beyond the standard of care for this study. Measurements and Main Results: During the verification phase, model performance was prospectively tested on 145 observations in a convenience sample of 29 patients. Median age was 60 years (54–66 d) with a median Sequential Organ Failure Assessment score of 9.5 (interquartile range, 5.0–14.0). The most common source of sepsis was pneumonia, followed by hepatobiliary. The observations were made during the first 24 hours of the ICU admission with one-step interventions, comparing the output in the digital twin with the real patient response. The agreement between the observed versus and the expected response ranged from fair (kappa coefficient of 0.41) for primary response to good (kappa coefficient of 0.65) for secondary response to the intervention. The most common error detected was coding error in 50 observations (35%), followed by expert rule error in 29 observations (20%) and timing error in seven observations (5%). Conclusions: We confirmed the feasibility of development and prospective testing of causal artificial intelligence model to predict the response to treatment in early stages of critical illness. The availability of qualitative and quantitative data and a relatively short turnaround time makes the ICU an ideal environment for development and testing of digital twin patient models. An accurate digital twin model will allow the effect of an intervention to be tested in a virtual environment prior to use on real patients.
Predictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: a systematic review of a globally representative sample
Hasan, Irtiza , Rashid, Tasnuva, Suliman, Sarah T., Amer, Hatem , Chirilă, Răzvan M. , Mai, Martin L., Khouzam, Samir , Heilig, Charles W., Wadei, Hani M. , Suliman, Sarah, Jarmi, Tambi , Amer, Hatem , Wadei, Hani M , Mai, Martin L., Franco, Pablo Moreno

Mayo Clinic

Romanian Journal of Internal Medicine | November 17, 2020 | Volume: 59 | Issue: 1 | Pages: 10-42

10.2478/rjim-2020-0034 | PMID 33155999 Get It

Abstract Introduction. COVID-19 presents a special challenge to the kidney transplant population. Methods. A systematic review of articles that examined COVID-19 in kidney transplant recipients was performed. Patients’ demographics, clinical, laboratory and radiological presentations, immunosuppression modification, and COVID-19 specific management were abstracted and analyzed. COVID-19 severity was classified into mild, moderate, and severe. Disease outcome was classified by whether the patient was discharged, still hospitalized, or died. Results. 44 articles reporting individual data and 13 articles reporting aggregated data on 149 and 561 kidney transplant recipients respectively with COVID-19 from Asia, Europe and America fulfilled all inclusion and exclusion criteria. Among studies reporting case specific data, 76% of cases had severe disease. Compared to patients with mild/moderate disease, patients with severe disease had higher CRP, LDH, Ferritin, D-dimer and were more likely to have bilateral lung involvement at presentation and longer time since transplantation (P < 0.05 for all). Recipients’ age, gender and comorbidities did not impact disease severity. Patients with severe disease had a more aggressive CNI reduction and more antiviral medications utilization. Outcome was reported on 145 cases, of those 34 (23%) died all with severe disease. Longer duration from transplant to disease diagnosis, hypoxia and higher LDH were associated with mortality (P < 0.05). Different immunosuppression reduction strategies, high dose parenteral corticosteroids use and various antiviral combinations did not demonstrate survival advantage. Similar finding was observed for studies reporting aggregated data. Conclusion. COVID-19 in kidney transplant patients is associated with high rate of disease severity and fatality. Higher LDH and longer time since transplantation predicted both disease severity and mortality. None of the COVID-19 specific treatment correlated with, or improved disease outcome in kidney transplant recipients.
COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart
Bois, Melanie C. , Boire, Nicholas, Layman, Andrew J. , Aubry, Marie-Christine, Alexander, Mariam P., Roden, Anja C. , Hagen, Catherine E. , Quinton, Reade A. , Majumdar, Ramanath, Jenkins, Sarah M. , Kipp, Benjamin R. , Lin, Peter T. , Maleszewski, Joseph J. , Boire, Nicholas A, Hagen, Catherine E , Layman, Andrew J. , Larsen, Christopher Patrick , Erben, Young

Mayo Clinic

Circulation | November 16, 2020 | Volume: 143 | Issue: 3 | Pages: 230-243

10.1161/circulationaha.120.050754 | PMID 33197204 Get It

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its resultant clinical presentation, coronavirus disease 2019 (COVID-19), is an emergent cause of mortality worldwide. Cardiac complications secondary to this infection are common; however, the underlying mechanisms of such remain unclear. A detailed cardiac evaluation of a series of individuals with COVID-19 undergoing postmortem evaluation is provided, with 4 aims: (1) describe the pathological spectrum of the myocardium; (2) compare with an alternate viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) provide the first description of the cardiac findings in patients with cleared infection. Methods: Study cases were identified from institutional files and included COVID-19 (n=15: 12 active, 3 cleared), influenza A/B (n=6), and nonvirally mediated deaths (n=6). Salient information was abstracted from the medical record. Light microscopic findings were recorded. An angiotensin-converting enzyme 2 immunohistochemical H-score was compared across cases. Viral detection encompassed SARS-CoV-2 immunohistochemistry, ultrastructural examination, and droplet digital polymerase chain reaction. Results: Male sex was more common in the COVID-19 group ( P =0.05). Nonocclusive fibrin microthrombi (without ischemic injury) were identified in 16 cases (12 COVID-19, 2 influenza, and 2 controls) and were more common in the active COVID-19 cohort ( P =0.006). Four active COVID-19 cases showed focal myocarditis, whereas 1 case of cleared COVID-19 showed extensive disease. Arteriolar angiotensin-converting enzyme 2 endothelial expression was lower in COVID-19 cases than in controls ( P =0.004). Angiotensin-converting enzyme 2 myocardial expression did not differ by disease category, sex, age, or number of patient comorbidities ( P =0.69, P =1.00, P =0.46, P =0.65, respectively). SARS-CoV-2 immunohistochemistry showed nonspecific staining, whereas ultrastructural examination and droplet digital polymerase chain reaction were negative for viral presence. Four patients (26.7%) with COVID-19 had underlying cardiac amyloidosis. Cases with cleared infection had variable presentations. Conclusions: This detailed histopathologic, immunohistochemical, ultrastructural, and molecular cardiac series showed no definitive evidence of direct myocardial infection. COVID-19 cases frequently have cardiac fibrin microthrombi, without universal acute ischemic injury. Moreover, myocarditis is present in 33.3% of patients with active and cleared COVID-19 but is usually limited in extent. Histological features of resolved infection are variable. Cardiac amyloidosis may be an additional risk factor for severe disease.
COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining
Desai, Aakash , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | November 16, 2020 | Volume: 4 | Issue: 2 | Pages: 64-66

10.36401/jipo-20-x7 | PMID 35663538 Get It